If You Invested in Eikon Therapeutics (EIKN)

Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company developing medicines for serious unmet medical needs. The company operates as a drug discovery and clinical development business and reports a single operating segment focused on product candidates discovered or advanced through its proprietary technology platform. Its common stock trades on the Nasdaq Stock Market under the symbol EIKN.

Eikon’s pipeline includes multiple internally identified product candidates, including EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006. The company’s disclosed clinical work is concentrated in oncology. EIK1001 is being developed in non-small cell lung cancer, including first-line treatment of stage 4 disease. EIK1003 is being evaluated in cancer settings that include prostate cancer, breast cancer, and ovarian cancer, both as a monotherapy and in combination-based approaches. EIK1004 is a highly selective PARP1 inhibitor designed to cross the blood-brain barrier and is being studied in advanced solid tumors, including patients with active brain metastases.

The company’s business model is based on drug discovery, clinical development, and the potential advancement of product candidates through later-stage studies and regulatory pathways. As a clinical-stage biopharmaceutical issuer, Eikon’s operating disclosures center on research and development activity, clinical program progress, corporate financing, governance, and capital structure rather than commercial product sales.

Eikon is headquartered in Millbrae, California. The company completed its initial public offering in February 2026 and became a Nasdaq-listed public company with common stock registered under Section 12(b) of the Securities Exchange Act of 1934.